WISDOM: Personalized breast cancer screening and prevention by tumor subtype
WISDOM: A platform to optimize subtype-specific screening and prevention
This project offers personalized breast cancer screening and prevention plans based on each woman's individual risk and the types of tumors she is most likely to develop.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11191479 on NIH RePORTER |
What this research studies
If you join, the WISDOM program uses a risk model that combines clinical factors, race/ethnicity, breast density, polygenic risk scores, and genetic sequencing to predict not only breast cancer risk but the subtype you are most likely to get. The team is expanding enrollment and applying subtype-specific risk profiles to tailor screening schedules and prevention recommendations for fast- versus slow-growing cancers. The program includes four linked research projects that develop and test models, screening strategies, and prevention approaches within a large national cohort. Participation may involve providing health information, genetic samples, and following personalized screening guidance.
Who could benefit from this research
Good fit: Women in the United States who are eligible for routine breast cancer screening and willing to provide health and genetic information are ideal candidates.
Not a fit: People already diagnosed with active breast cancer, those outside the U.S., or individuals unwilling to share medical or genetic data may not receive benefit from participating.
Why it matters
Potential benefit: If successful, this could help detect aggressive breast cancers earlier while reducing unnecessary tests and side effects for many women.
How similar studies have performed: Smaller risk-based screening efforts have been done, but WISDOM is the first large U.S. study and applying subtype-specific risk predictions is a relatively new approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Esserman, Laura J — University of California, San Francisco
- Study coordinator: Esserman, Laura J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.